Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Supernus Pharmaceuticals Inc    SUPN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
37.6(c) 37.9(c) 38(c) 38.1(c) 38.7(c) Last
351 917 456 532 459 664 401 887 365 603 Volume
+1.08% +0.80% +0.26% +0.26% +1.57% Change
More quotes
Financials ($)
Sales 2017 301 M
EBIT 2017 87,5 M
Net income 2017 57,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 389 M
EBIT 2018 124 M
Net income 2018 81,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 35,48
P/E ratio 2018 25,51
Capi. / Sales2017 6,49x
Capi. / Sales2018 5,02x
Capitalization 1 953 M
More Financials
Company
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy.It also develops product candidates for the treatment of... 
Sector
Pharmaceuticals
Calendar
11/29 | 02:00pmPresentation
More about the company
Surperformance© ratings of Supernus Pharmaceuticals I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUPERNUS PHARMACEUTICALS I
11/09 SUPERNUS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
11/09 SUPERNUS PHARMACEUTICALS : Patent Issued for Method of Treatment of Aggression (..
11/09 SUPERNUS PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders (..
11/09 SUPERNUS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
11/08 Supernus to Present at Three November Healthcare Conferences
11/07 SUPERNUS PHARMACEUTICALS INC : Supernus Pharmaceuticals, Inc. to Host Earnings C..
11/07 SUPERNUS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
11/06 SUPERNUS PHARMACEUTICALS : tops Street 3Q forecasts
11/06 Supernus Announces Third Quarter 2017 Financial Results
11/01SUPERNUS PHARMACEUTICALS INC : quaterly earnings release
More news
Sector news : Specialty & Advanced Pharmaceuticals
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/21 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimises likely staff losses
11/20 FTSE recoups early losses as cyclicals recover
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
11/10 Sell Pandora - Cramer's Lightning Round (11/9/17)
11/08 Premarket analyst action - healthcare
11/07 Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q3 2017 Results - Earnin..
11/07 VALUATION DASHBOARD : Healthcare - Update
11/06 Supernus Pharmaceuticals beats by $0.02, beats on revenue
Chart SUPERNUS PHARMACEUTICALS I
Duration : Period :
Supernus Pharmaceuticals I Technical Analysis Chart | SUPN | US8684591089 | 4-Traders
Technical analysis trends SUPERNUS PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 50,1 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Jack A. Khattar President, CEO, Secretary & Director
Charles W. Newhall Chairman
Gregory S. Patrick Chief Financial Officer & Vice President
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Stefan K. F. Schwabe Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SUPERNUS PHARMACEUTICALS INC50.50%1 953
ABBVIE49.49%149 207
MERCK KGAA-8.66%13 693
KYOWA HAKKO KIRIN CO LTD30.41%10 861
JAZZ PHARMACEUTICALS PLC22.78%8 169
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD42.96%6 088